MARKETSPERPSLIVE125
Cash
Portfolio
TrendingElectionsPoliticsCultureSportsCryptoCommoditiesClimateEconomicsMentionsFinance

Tech & Science

PredictLive125AccountSocial
Product
Kalshi ProPerpetual FuturesMarketsIncentive programInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQFee scheduleTrading hoursRegulatoryTrust Center
© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.

Medicine

All markets
AI
AI Indices
Big Tech & Business
Education
Energy
Market Share
Medicine
Physics & Math
Public Health
Space
Medicine

Will the FDA approve CagriSema?

Before Jan 1, 2027
1.31x
Before Jul 1, 2027
1.19x
$5,498 vol4 markets
Medicine

When will the FDA approve Intellia Therapeutics’ lonvo-z?

Before October 2027
1.14x
Before 2028
1.08x
$6,197 vol3 markets
Biotech

FDA decision: Venglustat by Sanofi (this year)

Yes
1.18x
No
3.96x
$706 vol1 market
Medicine

Will the FDA approve a cure for Type 1 diabetes before 2033?

Yes
2.34x
No
1.60x
$9,732 vol1 market
Medicine

When will the FDA approve Compass Pathways’ COMP360 Psilocybin?

Before Mar 1, 2027
1.55x
Before Jan 1, 2027
3.18x
$18,384 vol5 markets
Eli Lilly

Will the FDA approve retatrutide?

Before Jul 1, 2027
2.01x
Before Jan 1, 2028
1.07x
$38,899 vol5 markets
Medicine

When will Beam Therapeutics submit a BLA for Risto-cel?

before December
1.79x
before 2027
1.55x
$22,822 vol5 markets
Medicine

When will Compass Pathways submit a NDA for COMP360 psilocybin?

before November
1.57x
before December
1.42x
$20,726 vol5 markets
Medicine

When will the FDA reclassify BPC-157 to Category 1?

Before 2027
2.24x
Before November
4.73x
$98,996 vol2 markets
Biotech

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

Yes
1.23x
No
3.40x
$1,117 vol1 market
Biotech

FDA decision: Ivonescimab by Summit Therapeutics (this year)

Yes
1.40x
No
2.59x
$7,397 vol1 market
Biotech

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)

Yes
1.07x
No
6.29x
$2,806 vol1 market
Biotech

FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (this year)

Yes
1.20x
No
3.66x
$1,073 vol1 market
Eli Lilly

Will the FDA approve VERVE-102?

Before 2030
1.67x
Before 2031
1.42x
$1,693 vol6 markets
Biotech

FDA decision: Bepirovirsen by GlaxoSmithKline (this year)

Yes
1.01x
No
10.4x
$2,575 vol1 market
Biotech

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

Yes
1.06x
No
7.25x
$831 vol1 market